Potential CAR-T treatment centers announced (England)

Thank you to my NHS England Cancer Pharmacist colleagues for sharing the Information on the ‘potential’ treatment sites for delivery of CAR-T therapy in England.  As yet we are unaware of potential sites in the rest of the home nations, so would be grateful if BOPA members can share any relevant information on this exciting new cancer treatment via our forums or via email to [email protected] so we can share

NHS England is pleased to confirm that the following 8 centres have been selected for the first JACIE inspections for accreditation in delivering Immune Effector Cell therapy, based on their submissions, geographical access and advice from JACIE and industry partners:
 
•         Great Ormond Street Hospital NHS Foundation Trust     
•         King’s College Hospital NHS Foundation Trust     
•         Manchester University Hospitals NHS Foundation Trust (MRI /Royal Manchester Children’s Hospital)     
•         The Christie NHS Foundation Trust
•         The Newcastle Upon Tyne Hospitals NHS Foundation Trust         
•         University College London Hospitals NHS Foundation Trust
•         University Hospitals Birmingham NHS Foundation Trust                
•         University Hospitals Bristol NHS Foundation Trust
 
Further instructions are being sent to the sites identified for inspection.
 
This is the first phase of a national implementation of CAR T cell therapy with further phases expected in due course.
 
 

Latest News

By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
By BOPA IO SAG on 23rd April 2025

Toolkit for Immunotherapy IV to SC switch

Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…

Read article
By BOPA E&T subcommittee on 17th April 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…

Read article
By BOPA research subcommittee on 17th April 2025

Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…

Read article